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Opinion statement
Inflammatory bowel diseases (IBD) are a group of chronic inflammatory gastrointesti-
nal (GI) disorders, mainly represented by Crohn's disease and ulcerative colitis.
Although the etiology of IBD is not fully understood, there is substantial evidence that
immunologic, genetic, and environmental factors are the main contributors in IBD
pathogenesis. Conventional therapies for IBD include anti-inflammatory and immuno-
suppressive drugs, such as 5-aminosalicylic acid, corticosteroids, antibiotics, and bio-
logicals, such as anti-TNFα antibodies. However, because of low efficacy and high risk
of side effects, there is a clear need for the development of novel and efficient phar-
macologic strategies in IBD treatment. Among various complementary and alternative
medicine (CAM) approaches, which are used for the treatment of gastrointestinal (GI)
disorders, traditional Chinese medicine (TCM) is one of the most developed and diver-
sified. TCM encompasses methods and therapies that emerged over centuries and is
based mostly on ethnic wisdom and observations transmitted from generation to gen-
eration. In the recent years, the efficacy of TCM as treatment of IBD has been exten-
sively characterized in preclinical and clinical studies, which resulted in a significant
number of research reports. Moreover, the popularity of TCM among patients with
IBD has rapidly increased not only in Asia, but also in the Western hemisphere.
Inflammatory bowel diseases (IBD) is a group of
chronic inflammatory gastrointestinal (GI) disorders,
consisting of Crohn’s disease (CD) and ulcerative colitis
(UC) that may cause a substantial worsening of life qual-
ity. Patients suffering from IBD often require lifelong
pharmacologic treatment and sometimes even surgical in-
terventions. To achieve a successful management of IBD,
strong adherence to medication is essential and address-
ing patients’physical andperceptual barriers to adherence
is crucial in improving their health status [1••].
Nowadays, conventional medicine is offering a broad
range of anti-IBD drugs, including corticosteroids, immu-
nosuppressants, antibiotics, and biologicals, such as anti-
tumor necrosis factor α (anti-TNF-α) antibodies [2, 3].
Some of these conventional anti-IBD drugs are associated
with the risks of adverse events, such as metabolic dereg-
ulation leading to obesity (for corticosteroids), or adverse
skin reactions for anti-TNF-α antibodies [4, 5]. Moreover,
none of the drugs presently available, which are used for
anti-IBD therapy, are effective enough to provide com-
plete and life-long relief for the patients.
One of the most threatening risks, which IBD patients
are exposed to, is the risk of development of colorectal can-
cer (CRC) as a result of the chronic inflammatory state in
the lower GI tract. Literature data indicates that chronic in-
flammation, which underlies colitis-associated colorectal
cancer (CACRC), may contribute to the development of
up to 25 % of all diagnosed colorectal tumors [6].
Chronic accumulation of active neutrophils, macro-
phages, and dendritic cells in the lamina propria and the
colonic mucosa during inflammation is accompanied by
the release of several cytokines, such as TNF-α and IL-1β
[7], as well as reactive nitrogen and oxygen species [8],
which are known to induce genetic mutations.
Subsequently, the DNA damage and instability of micro-
satellite sequences in the colonic cells may result in activa-
tion of proto-oncogenes. For example, critical roles of
activated NF-κB, phospho-NF-κB and STAT3, which act
as nonclassical oncogenes in CRC and other cancers have
been reported [9]. The most effective methods of CACRC
treatment are cytotoxic drugs, radiotherapy, or resection
of tumor area. Low selectivity between cancer and
healthy cells and a major risk of side effects, often com-
bined with poor efficacy and the risk of relapse are the
main reasons for which new therapies against CRC are
urgently needed [10].
Over the last few years the popularity of comple-
mentary and alternative medicine (CAM) among IBD
and CACRC patients has been systematically increas-
ing, mainly because it is perceived as natural and effec-
tive [1••]. CAM generally denotes medical theories and
practices, which are outside the realm of conventional,
western medicine. Another feature, which separates
CAM from conventionalmedicine, is a holistic approach
to patient care, calling on self-healing by the body and
being applied in an individualized way [11]. CAM en-
compasses a vast and strongly diversified spectrum of
therapeutic procedures, as well as systematic and com-
prehensive concepts of disease treatment,which includes
traditional practices arising from tribal traditions and
ethnic wisdom. Practices of alternative medicine are of-
ten based on ideas, which discriminate modern patho-
physiology and pharmacology, relying more on
traditional practices and on ‘natural’ remedies, which
are being perceived as less toxic than conventional drugs
[11]. One of the common features of CAM is a minor
number of scientific data available in the form of con-
trolled trials for either its efficacy or safety.
Various studies, including cohort and population-
based surveys, have shown that the use of CAM, with acu-
puncture, Ayurvedic medicine, homeopathy, and herbal
medicine, is common among IBD patients from all age
groups [1••, 11–15]. The percentage of IBD patients using
CAM in North America and Europe has been estimated at
21 % up to even 60 % [1••]. In a recently published sys-
tematic review on herbal therapy in IBD by Ng et al
[1••], it has been shown that younger age, female gender,
higher education level, adverse drug reactions from IBD
medication, extra-intestinal manifestations, perceived
stress, and prolonged and intensive courses of steroids
are associated with the preference to use of CAM by IBD
patients over other forms of therapy [1••].
Traditional Chinese medicine (TCM) is one of the
most developed branches of CAM in the world.
Methods offered by TCM range from acupuncture,
through homeopathy, to the vast number of herbal
preparations, often of yet unknown composition and
mechanism of action. In this review we refer to the
use of TCM in the treatment of GI tract disorders, with
particular attention given to IBD and CACRC. We will
try to shed a light on the effectiveness of different prac-
tices and therapeutic preparations derived from TCM.
We will also discuss experimental in vitro and in vivo
results obtained from systematic literature search, car-
ried out by consulting 13 electronic scientific data-
bases including MEDLINE, SCOPUS, Web of Science,
Directory of Open Access Journal; electronic editorial
networks, such as BMJ, Blackwell, Elsevier, Karger,
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Nature Publishing Group, Springer; literature distribu-
tors, such as OVID Journals and EBSCO; clinical trials
databases, such as CT and EU - CTR. The scientific pa-
pers were selected according to the time span ranging
from 2001 to present in case of in vivo studies on an-
imal models and from 1997 in case of human




& Depending on the extent of disease, management of IBD requires spe-
cific diet, pharmacologic treatment, and/or—in some cases—surgery.
First line of classical pharmacologic therapy includes nonsteroid and
steroid anti-inflammatory drugs (eg,mesalazine, budesonide), which is
often time-limited because of potential adverse events. The second
treatment option includes biologicals, such as anti-TNFα antibodies
(eg, infliximab). In severe cases of IBD a surgery is required, which in-
volves resection of the fragment of the inflamed intestine. CAM
methods are used in the group of patients where classical treatment did
not provide sufficient relief. Several scientific reports characterizing the
effectiveness of TCM products in animal models of IBD, as well as
clinical studies have been published so far, showing promising results
and providing an insight into the mechanisms that are beyond their
therapeutic activity (Table 1). Here, selected TCM medications, which
recently attracted most attention, will be discussed.
Chinese traditional medicine and IBD (animal studies)
& In 2011, Li et al [16] characterized the anti-inflammatory activity of
YunNan BaiYao (YNBY), aforetime also called Yunnan Pai-yao,
which is an amalgamation of various herbs and plants derived from
southern China formulated in powder or capsule [16]. In China it is
used as a low-cost medication for both, internal and external hem-
orrhage and open wounds, mainly because of its well-known anti-
hemorrhagic and hemostatic functions. Besides the paper by Li et al
there is a lack of English language literature concerning preclinical or
clinical evaluation of YNBY activity. Interestingly, the exact compo-
sition of YNBY is not widely known, because it is secured as a
Chinese intellectual property by the government [16]. Li et al re-
ported that YNBY can effectively reduce the severity of experimental
colitis in mice by both, immune-suppressing and wound-healing
mechanisms. It was shown that the administration of YNBY in
drinking water significantly reduced disease progress in DSS- and
TNBS-induced colitis. In both models YNBY reduced the levels of
pro-inflammatory cytokines, such as TNFα, IL-12, IFNγ, and IL-17 in
colon and serum [16]. Moreover, YNBY suppressed the growth of T-
and B-lymphocytes more significantly than the most commonly used
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first-line anti-IBD drugs, 6-mercaptopurine (6-MP) and 5-
aminosalicylic acid (5-ASA), showing no cytotoxicity to colonic cells
(Caco-2).
& In another study Huang et al [17] reported the anti-inflammatory
activity of 4 different Wedelia chinensis extracts in a mouse model
experimental colitis induced by DSS; water extract exhibited the
highest anti-inflammatory efficacy. W. chinensis is a traditional me-
dicinal herb, widely used in many Asian countries, with various
therapeutic properties, including cough-relieving, antipyretic, anti-
inflammatory and also hepato-protective [17]. Huang et al observed
that W. chinensis water extract significantly attenuated the symptoms
of colitis including diarrhea, rectal bleeding, and loss of body weight
[17]. It also reduced the shortening of colon length and histopath-
ologic damage caused by colonic inflammation [17]. The anti-in-
flammatory activity ofW. chinensis water extract possibly results from
its immunosuppressive activity on T-cells. It has been demonstrated
that oral administration of W. chinensis affected the levels of regula-
tory cytokines (TNF-α, IL-4, IFN-γ, IL-17, TGF-β, and IL-12) showing
that this kind of treatment can suppress Th1 and Th17, but not Th2
responses in colon tissues of DSS-treated colitic mice [17]. Moreover,
W. chinensis water extract proved to be nontoxic to mice when ad-
ministrated at high doses (100–1000 mg/kg) [17].
& Cao et al reported the effect of Changtai granules (CTG) on chronic
TNBS-induced colitis in rats [18]. CTG is a traditional Chinese for-
mula consisting of herbs, such as Huangbai (Phellodendron amurense)
[18]. CTG exhibits a variety of pharmacologic effects including an-
algesic, anti-bacterial, anti-inflammatory and anti-diarrheal [18]. The
study of Cao showed that CTG was more potent than dexametha-
sone (DX) in amelioration of colitis in rats, but it should be noted
that CTG was used in a substantially higher dose than DX. CTG ef-
fectively inhibited the activity of granulocytes, macrophages, and
monocytes in a dose-dependent manner. It also caused a substantial
decrease in myeloperoxidase (MPO) activity and ulceration in co-
lonic mucosal tissue, thus the immunosuppressive mechanism of
CTG action has been suggested. Furthermore, administration of CTG
significantly prevented body mass loss, and decreased frequency of
diarrhea in TNBS-treated rats, when compared with the control ani-
mals [18].
& For thousands of years, mushrooms have been considered in TCM as
an edible medicinal resource. For example, Grifola frondosa (GF) has
been used as a remedy for pain and inflammation in Southeast Asia.
Studies demonstrated that extracts from fruiting body or liquid-cul-
tured mycelium of GF display considerable biological activities, such
as anti-tumor, anti-mutagenic, anti-hypertensive, anti-diabetic and
antioxidative [19–21]. Lee et al have shown that oral administration
of GF water extract (GFW) at the dose of 1 g/kg reversed the symp-
toms of colitis (weight loss, colon ulceration, TNF-α expression in
the tissue) to the same extent as 5-ASA at the dose of 0.1 g/kg (i.p.)
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[21]. Moreover, GFW significantly reduced the MPO activity, indi-
cating the reduction of neutrophil influx into the colonic tissue.
Additionally, Lee et al tested GFW in the in vitro model of IBD on
HT-29 cells. They demonstrated that in the coculture of HT-29 with
U937 human monocytic cells, the TNF-α-induced monocyte adhe-
sion to HT-29 cells was significantly suppressed by GFW (10, 50, and
100 μg/ml) [21]. The GFW-induced reduction of adhesion was cor-
related with the suppressed expression of MCP-1 and IL-8, major
IBD-associated cytokines and decreased transcriptional activity of
NF-κB [21]. These results suggest that GFW alleviates colonic in-
flammation by suppressing production of TNF-α and its signaling
through NF-κB, which results in a lowered expression of pro-in-
flammatory chemokines [21].
& TCM medications for GI disorders are often in the form of herbal
retention enema. Recently, Wu et al evaluated the therapeutic effect
of Changlu Enema (CE) in the mouse model of UC, induced by
colonic mucosa protein immunization [22]. Authors showed that
after 21 days of medication the UC activity index was significantly
lower and the body weight was higher than in the mice treated with
saline only. Moreover, it has been shown that pathologic (micro-
scopic) changes and inflammatory response in colonic tissue were
reversed after treatment with CE and the improvement was more
significant than in the salicylazosulfapyridine (SASP)-treated group
[22]. In another study Guo et al characterized the pharmacologic
action of a TCM herbal enema in the rat model of UC induced by
administration of 2,4-dinitrochlorobenzene (DNCB) and acetic acid
[23]. The formulae of TCM herbs for enema consisted of Huangqi
(Astragalus), Dahuang (Caulis Fibraureae), Huangbai (Cortex
Phellodendri), Wubeizi (Galla chinensis) and Baiji (Rhizoma Bletillae)
[23]. The study showed that the TCM herbal enema was more potent
than SASP in the treatment of UC [23]. Moreover, it has been showed
that treatment with TCM herbal enema resulted in a reduced ex-
pression of IL-6, TNF-α and IFN-γ [23]. The authors suggested that
the mechanism of therapeutic action of TCM herbal enema is asso-
ciated with the regulation of immune response in the colonic mu-
cosa and inhibition of macrophage/monocyte and granulocyte
activity.
Chinese traditional medicine and IBD (human studies)
& Even though some authors believe that the attempts to characterize
the effectiveness of TCM products using randomized-controlled trials
(RCTs) are deceptive in view of their exclusion from the realms of
scientific hypotheses and difficulties in formulation of endpoints,
there are several TCM products that successfully passed animal
studies and were introduced to trials on IBD patients (Table 2)
[11, 24, 25]. Zhang et al evaluated the anti-inflammatory activity of
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Xilei-san, a traditional Chinese herbal medicine, in an 8-week dou-
ble-blinded randomized study on 35 subjects with mild-to-moder-
ately active ulcerative proctitis [26]. The effect of Xilei-san was
compared with DX enemas. The study showed that both treatments
produced a significant improvement of clinical, endoscopic, and
histologic score [1, 26].
& In another RCT, Fukunaga et al characterized the potential of Xilei-
san to induce remission in 30 patients with intractable ulcerative
proctitis [27]. Subjects were treated with topical mesalazine or cor-
ticosteroids (4 weeks) and then randomized into Xilei-san supposi-
tories or placebo (2 weeks). In the Xilei-san-treated group,
significantly more patients achieved remission (clinical disease index
≤4) compared with placebo (PG0.04) [27]. Histologic improve-
ments, as well as relapse rate at 180 days were significantly lower in
Xilei-san-treated group compared with placebo [1••, 27].
& A TCM product called Kui jie qing (KJQ) was used in a form of enema
given 4 times daily to 95 patients with active UC [28]. This form of
treatment was compared with conventional anti-IBD drugs, including
suplhasalazine (1.5 g 3 times daily), oral prednisolone (30 mg once
daily) and prednisone enemas (20 mg 4 times daily). After 20 days of
treatment authors reported a 95 % effectiveness rate for KJQ and 62 %
for conventional drugs, based on the comparison of cure and im-
provement between the groups [28]. However, results presented in this
study cannot be considered conclusive as authors did not provide clear
definition of terms “cure” and “improvement”, which were used in this
paper as major determinants of final conclusion [1••, 11].
& A recent paper by Sandborn et al demonstrates results from a large
randomized double-blinded, placebo controlled trial comparing the
extract from an Asian plant Andrographis paniculata (HMPL-004) to
placebo in 224 patients with UC [29••]. A. paniculata is cultivated in
Southeastern Asia, where it has been traditionally used to treat in-
fections. For millennia A. paniculata was used in traditional, as well as
tribal medicine in China, India, and some other countries. In vitro, as
well as in vivo studies showed that extracts from A. paniculata inhibit
formation of oxygen derived free radicals and display anti-inflam-
matory activity. The major active compound in A. paniculata extracts
is andrographolide, which blocks the activity of NF-κB, known to be
the central transcriptional factor of genes involved in immunologic
responses [30, 31]. Sandborn et al showed that treatment with
HMPL-004 in a dose of 1.8 g daily resulted in a greater clinical re-
sponse than placebo (P=0.018), but did not affected the remission
rate in 8 weeks (P=0.101) [29••]. A second randomized double-
blinded, placebo controlled multicenter study (n=120) showed that
an 8-week therapy with HMPL-004 was as potent as mesalazine in
the treatment of mild-to-moderate UC [32]. Authors observed no
significant difference between experimental groups, thus suggested
that HMPL-004 is a promising alternative to mesalazine in UC.
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& The anti-inflammatory activity of TCM herbs have also been evaluated
in patients with CD. Tripterygium wilfordii Hook F (TWHF) is a TCM
herbal remedy with immunomodulatory and anti-inflammatory ac-
tivities. Preclinical studies demonstrated that extracts from TWHF in-
hibit the expression of pro-inflammatory cytokines, adhesion
molecules, and matrix metalloproteinases by macrophages, lympho-
cytes, synovial fibroblasts, and chondrocytes [33]. Ren et al evaluated
the ability of T2, a major constituent of TWHF extracts, to induce the
remission in 20 patients with active CD [34]. In this study the patients
were treated with T2 pills for 12 weeks (60 mg daily). Crohn's disease
activity index (CDAI) scores rapidly decreased during first 8 weeks of
treatment and reached minimum in week 10 [34]. Moreover, levels of
C-reactive protein (CRP) and pro-inflammatory cytokines, such as TNF-
α and IL-1β in plasma significantly decreased at the outset of treatment
[34]. It has been also shown thatTripterygiumwilfordii (TW)may prevent
the postoperative recurrence of CD at least to the same extent as
mesalazine. In a randomized study by Tao et al 45 adult cases of post-
operative CDwere randomly divided into 2 groups, which received TW
or mesalazine after operation [35]. There was no recurrence of the dis-
ease in both groups after 3 months. In 6 months, a similar percent of
patients relapsed in TW- and mesalazine-treated groups (18.2 % vs
21.7 %, respectively). In 1 year, 45.5 % of patients in TW-treated group
and 60.9%patients inmesalazine-treated group relapsed. Finally, there
were no significant differences between experimental groups during the
whole study [35]. In another study, 39 adult postoperative CD patients
were enrolled in a randomized, placebo-controlled trial. Patients were
treated with TW or SASP in 2 weeks after operation [36]. In the TW-
treated group the recurrence of the disease was ascertained in 1 patient
(5.6%) and 22.2%patients had endoscopic recurrence, comparedwith
4 patients (25.0 %) and 56.2 % in SASP-treated group [36]. These 2
studies showed that TW is as potent as conventional drugs in preventing
recurrence of postoperative CD.
& Recently, Ling et al evaluated the anti-IBD activity of another Chinese
herbal preparation administered by oral intake or retention enema in
78 patients for 30 days [37]. The preparation was made of various
herbs, including Radix Astragalus, Radix Codonopsis pilosula, Rhizoma
Atractylodes alba, Semen Coicis, Radix Aucklandiae, Radix Angelica
Sinensis, charred Massa Fermentata Medicinalis, Fructus Hordei
Germinatus, Herba Epimedii, Radix Glycyrrhiza, Radix Paeoniae lactiflora
alba, and Radix Pueraria [37]. Preparation was administered orally
twice daily, at 100 mL each time and/or in the form of the colon
retention enema, implemented for 45 minutes every day. The group
treated with both, oral intake and enema showed the best outcomes
in all aspects of clinical effectiveness and these results were signifi-
cantly different from other groups [37]. There were no significant
differences in main symptoms, colonoscopic scores and histopa-
thology of the colonic membrane between patients receiving TCM
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preparation by enema only and conventional treatment (ETIASA)
[37]. These observations led to the conclusion that TCM herbal drugs
administered by both, oral intake and retention enema, are effective
in the treatment of IBD. Also, these results indicate that such a mode
of therapy, combining both systemic and local administration of
TCM herbal drugs is particularly effective in the treatment of IBD.
Colorectal cancer (CRC)
& CRC is one of the most frequently diagnosed malignant cancers. It is
the second most common malignancy in the developed countries
and a significant cause of mortality, being the fourth cause of death
in the world. The most effective methods of CRC treatment currently
available are cytotoxic drugs, radiotherapy or resection of tumor area.
In patients with locally advanced rectal cancer, preoperative chemo-
radiotherapy has proven to significantly improve local control and
cause a lower treatment-related toxicity compared with postoperative
adjuvant treatment. The low selectivity between cancer and healthy
cells and a major risk of side effects, often combined with the risk of
relapse are the main reasons for which new therapies against CRC are
urgently needed. Of note, the human studies on the efficiency of
TCM in CRC cited in this review should be considered with caution
because of several weaknesses: lack of important information about
blinding, randomizing and excluded or included patients. This re-
view indeed shows some positive findings, but the quality of the
trials precludes the making of any definitive statements. Well-con-
ducted randomized clinical trials are needed to confirm any benefit
of traditional Chinese herbs in the treatment of CRC.
Chinese traditional medicine and CRC (animal studies)
& Formany years, Shikonin and its derivatives have been used in TCM for
the prevention and treatment of various diseases, including cancer. One
of the derivatives, β,β-demethylacrylshikonin (DA), a major compo-
nent of the lithospermum erythrorhizon roots, was identified as a po-
tential inhibitor of hepatocellular carcinoma growth [38, 39]. Further
studies reported that DA displays evenmore pharmacologic properties,
such as anti-inflammatory, antioxidant, and antiplatelet [40]. Yingying
et al showed that systemic therapywithDA can inhibit tumor growth in
animals, whichwas demonstrated by usingHCT-116 xenografts inmice
[41]. Once HCT-116 cells were injected subcutaneously into upper left
flank region ofmice, the animals were divided into 4 groups and treated
daily with DA (0.3, 0.6, and 1.2 mg/kg) or saline as a negative control
[41]. Allmice were sacrificed onDay 13 after inoculationwithHCT-116
cells. Treatment with DA significantly reduced tumor growth and ex-
hibited no toxicity, measured by body weight decrease [41]. The
mechanismofDA action is arguably associatedwith inducing apoptosis
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of tumor cells; the authors found that DA decreased the expression of
anti-apoptotic protein Bcl-2 and increased expression of pro-apoptotic
Bax protein [41].
& Shikunshito-Kamiho (SKTK) is a TCM preparation composed of 8
crude drugs (Ginseng radix, Hoelen, Atractylodis Rhizoma, Glycyrrhizae
Radix, Prunellae Spica, Ostreae Testa, Laminaria Thallus, Sargassum),
which serves as a cure for CRC in oriental medicine. Yoo et al in-
vestigated the anticarcinogenic effect of SKTK on 1,2-dimethylhy-
drazine (DMH)- induced CRC in mice [42]. The animals received
injections of carcinogen (DMH) once a week for 10 weeks while
being fed with diet containing 0.5 % or 1.5 % extracts of SKTK [42].
The water extracts of SKTK were provided to the diet for 5 weeks after
last injection of DMH. Eventually, the authors evaluated fecal en-
zymes, such as β-glucuronidase, tryptophase and urease, and the
aberrant crypt foci (ACF) formation in murine colon. β-
Glucuronidase and tryptophanase were reduced in both groups,
whereas the level of urease was significantly reduced only in mice fed
with 1.5 % SKTK [42]. The number of ACF in the colon, which are
regarded as putative preneoplastic lesions of rodent and humans,
was significantly decreased in the group fed with both concentrations
of SKTK, compared with positive control (no SKTK) [42].
& Sophoridine (SRI) is one of the quinolizidine alkaloids, which were
extracted from seeds of Saphora alopecuroides L. [43]. This traditional
Chinese herb has been used for clearing heat and removing toxins for
hundreds of years. Previous research showed that SRI is one of the
most active compounds occurring in this herb and can significantly
inhibit the growth of colon adenocarcinoma cells [44]. Lei et al ex-
plored a potential anti-colorectal carcinoma effect of sophoridine
using mice with tumor xenograft of SW480 cells subcutaneously in
the mice armpit [45]. The anti-tumor activity of SRI (15 and 25 mg/
kg, 5 days a week) was compared with 5-fluorouracil (30 mg/kg,
3 days a week), both given through i.p. injection. The experiment in
SW480 tumor-bearing mice demonstrated that the higher dose of SRI
had a significant effect on tumor inhibition [45]: the average tumor
volume in SRI (25 mg/kg) group was significantly lower than in the
control group (0.579±0.144 vs 1.149±0.142 cm3, respectively).
Based on the in vitro and in vivo experiments, authors concluded
that SRI acts as a pro-apoptotic factor in SW480 cells. The immu-
nocytochemistry suggested that SRI may activate caspase-3-depen-
dent pathways, leading to cell apoptosis. Of note, after treatment
with SRI there was no change in animal behavior; the animals ate
and defecated normally and their weight increased. The mice treated
with 5-fluorouracil (5-FU) ate less throughout the study; they also
weighed much less and developed bloody diarrhea in the later stages
of the treatment [45].
& Spica Prunellae, the fruit spikes of the perennial plant Prunella vulgaris
L, are used in TCM to treat poor vision, blood stasis, and edema.
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They are also believed to possess anti-cancer properties. Lin et al re-
ported that the extract of Spica Prunellae promotes apoptosis of hu-
man CRC cells and displays anti-angiogenic activity in vitro [46]. In
another study the authors investigated the anti-carcinogenic activity
of Spica Prunellae using a mouse HT-29 cell xenograft model [46]. In
the course of the experiment, the animals received the ethanol extract
of SP (EESP) at the dose of 6 g/kg or saline (both p.o.) once daily,
5 days a week for 16 days [46]. Body weight and tumor growth were
measured every 2 days. EESP treatment significantly reduced both,
tumor volume and weight compared with control mice. Moreover,
EESP treatment did not affect body weight. These results indicate that
EESP effectively suppresses CRC growth in vivo without apparent
signs of toxicity. The gathered data suggested that EESP promotes
CRC cell apoptosis, as well as inhibits cell proliferation and tumor
angiogenesis. According to Lin et al the mechanism of EESPs activity
is associated with suppression of the STAT3 pathway activation and
regulation of the expression of Bcl-2, Bax, Cyclin D1, CDK4, VEGF-A,
and VEGFR-2 in xenograft mice [46].
Chinese traditional medicine and CRC (human studies)
& To date, someof themost promising TCMcompounds have been tested
in patients with diagnosed CRC (Table 2). Recently, Zhong et al pub-
lished a meta-analysis of 20 trials that evaluates the efficacy of tradi-
tional Chinese herbal therapies as an adjunctive therapy for CRC [47].
All studies taken into consideration included patients with pathologi-
cally or cytologically confirmed CRC treated with chemotherapy. Only
randomized controlled trials were eligible and studies comparing che-
motherapy with or without TCM were considered. Total survival rate
and tumor response were regarded as the final outcome. It was found
that the chemotherapy combined with TCM significantly increased 1-
and 3-year survival rate (OR 2.41, 95 % confidence interval (CI) 1.32–
4.41; OR 2.40, 95 % CI 1.49–3.87; 5 studies, n=396) when compared
with chemotherapy alone [47]. Combined therapy slowed CRC pro-
gression (OR 0.5, 95 % CI 0.32–0.77; 7 studies n=269) and improved
quality of life (OR 3.43, 95 % CI 2.35–5.02, 9 studies, n=649) [47].
Moreover, TCM as an additive therapy significantly reduced adverse
effects of chemotherapy. This meta-analysis suggests that TCM may
become a potent and safe supplement to chemotherapy in the future.
However, a firm conclusion could not be made because of insufficient
quality of some trials included in the study [47].
& Yang et al evaluated the effectiveness of a comprehensive TCM
therapy on reducing the relapse and metastasis of stage II and III CRC
vs conventional Western medicine (WM) treatment [48]. There were
222 patients included into the trial with CRC on stage II or II diagnose;
staging standard was referred to the guidelines of the International
Union Against Cancer (IUAC). Patients were combined into 2 groups:
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treated with conventional WM (meant as R0 radical operation or che-
motherapy or/and radiotherapy according to National comprehensive
cancer network (NCCN) clinical guidelines) and treated with WM
combined with TCM, such as: Sijunzi Decoction, Chaihu Shugan
Powder, BazhenDecoction,Huachansu Tablet, Quxie capsule, Pingxiao
capsule [48]. The results showed that the relapse/metastasis rates in 1-,
2-, 3-, 4-, 5-yearwere lower in a groupwith TCMas adjunct therapy than
in the group with chemotherapy alone. Median relapse/metastasis time
was 26.5 months in the combined group and 16.0 months in group
treated with western medicine only [48].
& For hundreds of years, a TCMherbal preparation called PHY906 has been
used in Asia for treatment of GI disorders. PHY906 is composed of 4main
herbs: Scutulleria baicalensis Georgi, Paeonia lactiflora Pall, Glycyrrhiza
uralensis Fisch, and Ziziphus jujubeMill. In vivo studies on animal CRC
models showed encouraging results, demonstrating that therapy with
PHY906 combined with conventional drugs is more potent and less toxic
than the use of conventional drugs alone [49]. Recently, Kummar et al
conducted a phase I multicenter, double-blinded, randomized, placebo
controlled, dose escalation, cross-over study of PHY906 as amodulator of
irinotecan chemotherapy in patients with colorectal cancer [49], with 17
cases enrolled to the phase I study. Patients were treated according to the
IFL regimen (weekly dose of irinotecan 125 mg/m2, followed by
leucovorin at 20 mg/m2 and
5-fluorouracil at a doseof 500mg/m2)withPHY906orplacebo. The study
showed a reduction in incidence of diarrhea in patients treated with
PHY906, which resulted in a lower use of antidiarrheals. There was also a
trend toward lower frequency and severity of vomiting inpatients receiving
PHY906 as opposed to placebo [49].
& Yang et al evaluated the potency of Quxie Capsule on themedian survival
time and quality of life in patients with advanced CRC [50]. Forty patients
with CRC were enrolled to this randomized controlled clinical trial. All
patientswere treatedby routineCRCtherapy, including chemotherapyand
radiotherapy, additionally 1 group was administrated with Quxie capsule.
After 3 months of the treatment the fatality rate, survival time, median
survival time, time toprogressionandqualityof lifewere evaluated.Results
showed that Quxie capsule can prolong the fatality rate, survival time,
median survival timeand improvequality of life inpatientswithCRC [50].
& In another study Luo et al evaluated the effect of Quxie Capsule and
FuzhengCapsule in reducing relapse andmetastasis of CRC in stage II and
II after radical operation treatment (with addition radiotherapy or/ and
chemotherapy) [51]. A prospective cohort controlled studywas conducted
in 101 patientswithCRC, fromwhich 53were treatedwithQuxie Capsule
andFuzhengCapsule and48were givenno treatment. The rate and timeof
relapse and metastasis were observed after 1, 2, and 3 years. Both param-
eterswere higher in patients treatedwith TCM(average timeof relapse and
metastasis: 26.2±4.5 months in group treated with TCM and 14.2±
4.2 months in control group) [51]. Unfortunately, this study did not
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compare Quxie Capsule and Fuzheng Capsule to any form of conven-
tional anti-CRC treatment what substantially reduces the scientific im-
portance of the results obtained.
Concluding remarks
Conventional treatment of GI diseases is currently limited to pure overcoming of
their symptoms and often associated with severe adverse effects of the drugs used.
Application of TCM is getting more and more popular among IBD and CRC pa-
tients during recent years. Careful analysis of the experimental data leads to the con-
clusion that TCM methods are promising and in some cases they may worthily
replace conventional methods. However, there is yet insufficient number of con-
trolled trials evaluating potential efficacy of TCM approaches in IBD and CRC.
Although several products have been tested, the scientific evidence regarding their
efficacy or safety has not been adequate, and themajority of studies have produced
inconsistent results. There is an unquestionable need for further studies on TCM
methods in the treatment of GI disorders to establish their quality and safety.
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